You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said its coronavirus assay targets the nucleocapsid and envelope virus genes and is compatible with most RNA extraction methods and qPCR instruments.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.
Roche will have non-exclusive access to SpeeDx's existing tests and technology to enable expansion of diagnostic products for antibiotic resistance in STIs.
The test detects SARS-CoV-2 from nasopharyngeal swab specimens and runs on standard qPCR instruments, including Thermo Fisher's Applied Biosystems 7500 Fast machine.
The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.
Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
The firm said as part of a development study it is using a gut microbiome analysis tool developed in collaboration with Thermo Fisher Scientific.
The panel's developers at UPenn hope to validate and commercialize a non-invasive assay through a startup called Chip Diagnostics.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.